個(gè)人簡(jiǎn)介：

Jeff He is the Co-Founder & CEO at TandemAI. He brings 20+ year leadership experience in corporate strategy, business development, venture financing and operation.

Previously, Jeff co-founded HiFiBiO Therapeutics and served as its Chief Operating Officer since 2017. Prior to that, Jeff was co-founder & CFO at Harbour BioMed from 2015 to 2017. Before launching his entrepreneurial career, Jeff served as Executive Vice President of Strategy and Operation at ShangPharma/ChemPartner for 3 years. Mr. He also served as Senior Vice President at Texas Pacific Group (TPG), where he helped to privatize ShangPharma from the NYSE. Prior to TPG, Mr. He held management roles with increasing P&L responsibilities at Danaher/Fluke and Saint-Gobain. In his early career, he was a strategy consultant at Bain & Company and a senior financial analyst at Intel.

Mr. He received his MBA degree from Goizueta Business School at Emory University, M.S. degree in Economics from Shanghai Univ. of Science and Technology, and bachelor degree in engineering from Zhejiang University.

公司簡(jiǎn)介：

TandemAI是一家先進(jìn)的技術(shù)公司，致力于降低進(jìn)入藥物發(fā)現領(lǐng)域最先進(jìn)工具的門(mén)檻。我們的集成藥物發(fā)現平臺結合了一套專(zhuān)有的人工智能和基于物理的藥物發(fā)現工具、定制的超級計算基礎設施和大規模濕實(shí)驗室操作，使藥物發(fā)現中最先進(jìn)工具的訪(fǎng)問(wèn)民主化，并提升研究人員的體驗。?

TandemAI的科學(xué)家協(xié)作團隊與全球科學(xué)界合作，大幅提高臨床前候選藥物的成功率，并最終幫助改善等待新治療方案的患者的生活。

TandemAI目前的重點(diǎn)是幫助客戶(hù)推進(jìn)臨床前小分子候選藥物。我們的愿景是與客戶(hù)一起成長(cháng)，以支持他們在生物制劑和其他大分子療法方面的發(fā)現工作。